Osocimab, formerly known as BAY 1213790, represents a unique monoclonal immunoglobulin currently in clinical assessment for the therapy of several hematologic tumors. This molecule primarily targets CD38, a cell receptor overexpressed on cancerous cells in diseases like multiple myeloma and acute myeloid leukemia. Preclinical studies have indicated